{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T10:39:14Z","timestamp":1787049554301,"version":"build-2736575974"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Bergen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Idiopathic retinal vasculitis, aneurysms and neuroretinitis (IRVAN) is a rare ocular condition with an unresolved aetiology, different treatment practices and a risk of severe vision loss in refractory cases. There is sparse literature on the use of biologics, specifically TNF- \u03b1 inhibitors, in the management of IRVAN, emphasising the need for additional evidence in this therapeutic area.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We present a 49-year-old otherwise healthy Norwegian woman who experienced gradual bilateral visual deterioration and was diagnosed with IRVAN syndrome following extensive systemic and ophthalmological evaluation. Despite treatment with monthly bilateral intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections, which were initially combined with systemic corticosteroids and later with peripheral scatter laser photocoagulation, disease control was not achieved. At nadir, the best-corrected visual acuity (BCVA) was 0.4 in OD and 0.3 in OS. Eight months after treatment initiation, the TNF-\u03b1 inhibitor adalimumab was introduced in combination with methotrexate, and the subsequent clinical course was characterised by substantial and sustained improvement. The macroaneurysms regressed and the vasculitis subsided, leading to complete resolution of the peripapillary oedema and improvement of visual acuity to 0.9\u20131.0 bilaterally. At two years, the patient remained stable on adalimumab monotherapy without further intervention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Adalimumab may represent a safe and effective option for managing refractory IRVAN syndrome and could address the underlying pathology. Our findings underscore the importance of individualised therapeutic approaches and advocate further investigation of TNF-\u03b1 inhibitors as a viable treatment option for IRVAN.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12886-026-04692-1","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T08:39:47Z","timestamp":1772527187000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Adalimumab in the management of refractory idiopathic retinal vasculitis, aneurysms, and neuroretinitis (IRVAN) syndrome: a case report and literature review"],"prefix":"10.1186","volume":"26","author":[{"given":"Ala Bassam","family":"Qadan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Ibrahim","family":"Zafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Anass","family":"Tanveer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjarte Bondevik","family":"Berstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1227-7843","authenticated-orcid":false,"given":"Ragnhild Wivestad","family":"Jansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"issue":"7","key":"4692_CR1","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/s0161-6420(95)30907-4","volume":"102","author":"TS Chang","year":"1995","unstructured":"Chang TS, Aylward GW, Davis JL, Mieler WF, Oliver GL, Maberley AL, et al. Idiopathic retinal vasculitis, aneurysms, and neuro-retinitis. Retinal Vasculitis Study Ophthalmol. 1995;102(7):1089\u201397. https:\/\/doi.org\/10.1016\/s0161-6420(95)30907-4. PubMed PMID: 9121757.","journal-title":"Retinal Vasculitis Study Ophthalmol"},{"key":"4692_CR2","doi-asserted-by":"publisher","first-page":"251584142110708","DOI":"10.1177\/25158414211070880","volume":"14","author":"H Ali Khan","year":"2022","unstructured":"Ali Khan H, Ali Khan Q, Shahzad MA, Awan MA, Khan N, Jahangir S, et al. Comprehensive overview of IRVAN syndrome: a structured review of case reports and case series. Ther Adv Ophthalmol. 2022;14:25158414211070880. Epub 20220121. PubMed PMID: 35282003; PubMed Central PMCID: PMC8905214. https:\/\/doi.org\/10.1177\/25158414211070880","journal-title":"Ther Adv Ophthalmol"},{"issue":"4","key":"4692_CR3","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1080\/09273948.2020.1836234","volume":"30","author":"M Khairallah","year":"2022","unstructured":"Khairallah M, Khochtali S, Ksiaa I. Is there a true neuroretinitis in idiopathic retinal vasculitis, aneurysms, and neuroretinitis (IRVAN) syndrome ? Ocul Immunol Inflamm. 2022;30(4):845\u20137. PubMed PMID: 33331800.","journal-title":"Ocul Immunol Inflamm"},{"issue":"39","key":"4692_CR4","doi-asserted-by":"publisher","first-page":"e39768","DOI":"10.1097\/md.0000000000039768","volume":"103","author":"HF Tung","year":"2024","unstructured":"Tung HF, Wu JS, Chen SN. Successful treatments of idiopathic retinal vasculitis, aneurysms, and neuroretinitis (IRVAN) syndrome-related macular edema and exudation by intravitreal aflibercept injection in a senile patient: a case report. Med (Baltim). 2024;103(39):e39768. https:\/\/doi.org\/10.1097\/md.0000000000039768. PubMed PMID: 39331946; PubMed Central PMCID: PMC11441943.","journal-title":"Med (Baltim)"},{"issue":"3","key":"4692_CR5","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1097\/00006982-198300330-00005","volume":"3","author":"J Kincaid","year":"1983","unstructured":"Kincaid J, Schatz H. Bilateral retinal arteritis with multiple aneurysmal dilatations. Retina. 1983;3(3):171\u20138. https:\/\/doi.org\/10.1097\/00006982-198300330-00005. PubMed PMID: 6635351.","journal-title":"Retina"},{"issue":"1","key":"4692_CR6","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1186\/s12886-025-04236-z","volume":"25","author":"H Asaad","year":"2025","unstructured":"Asaad H, Hasan R. Idiopathic retinal vasculitis, aneurysms, and neuroretinitis (IRVAN) syndrome: a comprehensive literature review of a rare retinal vasculopathy. BMC Ophthalmol. 2025;25(1):396. https:\/\/doi.org\/10.1186\/s12886-025-04236-z.","journal-title":"BMC Ophthalmol"},{"issue":"4","key":"4692_CR7","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1089\/jop","volume":"27","author":"RA Cheema","year":"2011","unstructured":"Cheema RA, Al-Askar E, Cheema HR. Infliximab therapy for idiopathic retinal vasculitis, aneurysm, and neuroretinitis syndrome. J Ocul Pharmacol Ther. 2011;27(4):407\u201310. https:\/\/doi.org\/10.1089\/jop. Epub 20110512.","journal-title":"J Ocul Pharmacol Ther"},{"key":"4692_CR8","doi-asserted-by":"publisher","first-page":"103725","DOI":"10.1016\/j.amsu.2022.103725","volume":"77","author":"M Mansour","year":"2022","unstructured":"Mansour M, Al-Ghotani B, Abo-Shdeed B, Jannoud O. IRVAN syndrome: a case report and a literature review. Ann Med Surg (Lond). 2022;77:103725. https:\/\/doi.org\/10.1016\/j.amsu.2022.103725. Epub 20220504.","journal-title":"Ann Med Surg (Lond)"},{"issue":"2","key":"4692_CR9","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1080\/09273948.2022.2027466","volume":"31","author":"P Samalia","year":"2023","unstructured":"Samalia P, Sims J, Deva N. Idiopathic retinal vasculitis, aneurysms and neuroretinitis: clinical improvement with infliximab. Ocul Immunol Inflamm. 2023;31(2):437\u201344. 2027466. PubMed PMID: 35081005.","journal-title":"Ocul Immunol Inflamm"},{"issue":"3","key":"4692_CR10","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1080\/09273948.2022.2039209","volume":"31","author":"SBS Kanakath","year":"2023","unstructured":"Kanakath SBS, Saravanan AV, K SJ V. A Case of idiopathic retinitis vasculitis aneurysms and neuroretinitis (IRVAN) treated with adalimumab. Ocul Immunol Inflamm. 2023;31(3):627\u201330. PubMed PMID: 35316150.","journal-title":"Ocul Immunol Inflamm"},{"issue":"9","key":"4692_CR11","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1007\/s00347-024-02067-9","volume":"121","author":"J Klon","year":"2024","unstructured":"Klon J, Heinrich MA, Maa\u00df J, Kiraly L. [IRVAN syndrome]. Ophthalmologie. 2024;121(9):756\u20139. https:\/\/doi.org\/10.1007\/s00347-024-02067-9. Epub 20240702.","journal-title":"Ophthalmologie"},{"key":"4692_CR12","doi-asserted-by":"publisher","unstructured":"Van Winckel L, Casteels I, Schauwvlieghe PP. Idiopathic retinitis vasculitis aneurysms and neuroretinitis (IRVAN) treated with adalimumab: a case report. Retinal Cases Brief Rep 9900. https:\/\/doi.org\/10.1097\/ICB.0000000000001800 \u00a0PubMed PMID: 01271216-990000000-00535.","DOI":"10.1097\/ICB.0000000000001800"},{"key":"4692_CR13","doi-asserted-by":"publisher","unstructured":"Li J, Yu K, Rao NA, Toy BC. A case of refractory idiopathic retinitis, vasculitis, aneurysms, and neuroretinitis (IRVAN) responsive to infliximab and mycophenolate mofetil. Retin Cases Brief Rep. 2025. Epub 20250623. https:\/\/doi.org\/10.1097\/icb.0000000000001782. PubMed PMID: 40591948.","DOI":"10.1097\/icb.0000000000001782"},{"key":"4692_CR14","doi-asserted-by":"publisher","unstructured":"Mandura RA, Opdenakker G, Abu El-Asrar A. Long-term efficacy of infliximab therapy in idiopathic retinal vasculitis, aneurysms and neuroretinitis (IRVAN) syndrome. Ocular Immunology and Inflammation.1\u20135. https:\/\/doi.org\/10.1080\/09273948.2025.2530134","DOI":"10.1080\/09273948.2025.2530134"},{"issue":"3","key":"4692_CR15","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1227\/01.neu.0000170439.89041.d6","volume":"57","author":"T Jayaraman","year":"2005","unstructured":"Jayaraman T, Berenstein V, Li X, Mayer J, Silane M, Shin YS, et al. Tumor necrosis factor alpha is a key modulator of inflammation in cerebral aneurysms. Neurosurgery. 2005;57(3):558\u201364. https:\/\/doi.org\/10.1227\/01.neu.0000170439.89041.d6. discussion\u2009\u2013\u200964.","journal-title":"Neurosurgery"},{"issue":"4","key":"4692_CR16","doi-asserted-by":"publisher","first-page":"805","DOI":"10.2147\/vhrm.s2700","volume":"4","author":"T Jayaraman","year":"2008","unstructured":"Jayaraman T, Paget A, Shin YS, Li X, Mayer J, Chaudhry H, et al. TNF-alpha-mediated inflammation in cerebral aneurysms: a potential link to growth and rupture. Vasc Health Risk Manag. 2008;4(4):805\u201317. https:\/\/doi.org\/10.2147\/vhrm.s2700. PubMed PMID: 19065997; PubMed Central PMCID: PMC2597764.","journal-title":"Vasc Health Risk Manag"},{"issue":"8","key":"4692_CR17","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1016\/j.ophtha.2006.11.014","volume":"114","author":"MA Samuel","year":"2007","unstructured":"Samuel MA, Equi RA, Chang TS, Mieler W, Jampol LM, Hay D, et al. Idiopathic retinitis, vasculitis, aneurysms, and neuroretinitis (IRVAN): new observations and a proposed staging system. Ophthalmology. 2007;114(8):1526\u20139. .e1. PubMed PMID: 17678691.","journal-title":"Ophthalmology"},{"issue":"4","key":"4692_CR18","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1097\/icb.0000000000000692","volume":"14","author":"R Ameratunga","year":"2020","unstructured":"Ameratunga R, Donaldson M. Treatment of idiopathic retinal vasculitis, aneurysms, and neuroretinitis (IRVAN) with photocoagulation in combination with systemic immunosuppression. Retin Cases Brief Rep. 2020;14(4):334-8. https:\/\/doi.org\/10.1097\/icb.0000000000000692. PubMed PMID: 29261555.","journal-title":"Retin Cases Brief Rep"},{"key":"4692_CR19","doi-asserted-by":"publisher","unstructured":"Basha M, Brown GC, Palombaro G, Shields CL, Shields JA. Management of IRVAN syndrome with observation. Ophthalmic Surg Lasers Imaging Retina. 2014;45 Online:e18-22. Epub 20140501. https:\/\/doi.org\/10.3928\/23258160-20140331-02. PubMed PMID: 24766157.","DOI":"10.3928\/23258160-20140331-02"},{"issue":"1","key":"4692_CR20","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1016\/j.jfo.2013.04.010","volume":"37","author":"A Ennouri","year":"2014","unstructured":"Ennouri A, Makhoul D, Nubourgh I, Mistryh S, Caspers L, Willermain F. [Intravitreal and intravenous steroids in a case of Idiopathic retinitis, vasculitis and neuroretinitis (IRVAN) syndrome]. J Fr Ophtalmol. 2014;37(1):e5\u20138. https:\/\/doi.org\/10.1016\/j.jfo.2013.04.010. Epub 20131029.","journal-title":"J Fr Ophtalmol"},{"issue":"3","key":"4692_CR21","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.oftal.2012.07.027","volume":"89","author":"M Garcia Vilaro","year":"2014","unstructured":"Garcia Vilaro M, Bassaganyas Vilarrassa F, Vela Segarra JI, Buil Calvo JA. [Early treatment of idiopathic vasculitis, aneurysms and neuroretinitis (IRVAN). A case report]. Arch Soc Esp Oftalmol. 2014;89(3):117\u201320. https:\/\/doi.org\/10.1016\/j.oftal.2012.07.027. Epub 20121023.","journal-title":"Arch Soc Esp Oftalmol"},{"key":"4692_CR22","doi-asserted-by":"publisher","unstructured":"Ishikawa F, Ohguro H, Sato S, Sato M, Yamazaki H, Nakazawa M. A case of idiopathic retinal vasculitis, aneurysm, and neuroretinitis effectively treated by steroid pulse therapy. Jpn J Ophthalmol. 2006;50(2):181-5. https:\/\/doi.org\/10.1007\/s10384-005-0277-x. PubMed PMID: 16604399.","DOI":"10.1007\/s10384-005-0277-x"},{"issue":"2","key":"4692_CR23","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1159\/000341821","volume":"3","author":"C Mar\u00edn-Lamb\u00edes","year":"2012","unstructured":"Mar\u00edn-Lamb\u00edes C, Gallego-Pinazo R, Salom D, Navarrete J, D\u00edaz-Llopis M. Rapid regression of exudative maculopathy in idiopathic retinitis, vasculitis, aneurysms and neuroretinitis syndrome after intravitreal ranibizumab. Case Rep Ophthalmol. 2012;3(2):251\u20137. Epub 20120815. doi: 10.1159\/000341821. PubMed PMID: 22949913; PubMed Central PMCID: PMC3433025.","journal-title":"Case Rep Ophthalmol"},{"issue":"6","key":"4692_CR24","doi-asserted-by":"publisher","first-page":"599","DOI":"10.3928\/23258160-20131105-09","volume":"44","author":"GK Sawhney","year":"2013","unstructured":"Sawhney GK, Payne JF, Ray R, Mehta S, Bergstrom CS, Yeh S. Combination anti-VEGF and corticosteroid therapy for idiopathic retinal vasculitis, aneurysms, and neuroretinitis syndrome. Ophthalmic Surg Lasers Imaging Retina. 2013;44(6):599\u2013602. https:\/\/doi.org\/10.3928\/23258160-20131105-09. PubMed PMID: 24221466.","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"1","key":"4692_CR25","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1159\/000375481","volume":"6","author":"AO Saatci","year":"2015","unstructured":"Saatci AO, Ayhan Z, Take\u015f \u00d6, Yaman A, Bajin FM. Single bilateral dexamethasone implant in addition to panretinal photocoagulation and oral azathioprine treatment in IRVAN syndrome. Case Rep Ophthalmol. 2015;6(1):56\u201362. Epub 20150211. doi: 10.1159\/000375481. PubMed PMID: 25802506; PubMed Central PMCID: PMC4357687.","journal-title":"Case Rep Ophthalmol"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-026-04692-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-04692-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-04692-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:16:47Z","timestamp":1781637407000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12886-026-04692-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4692"],"URL":"https:\/\/doi.org\/10.1186\/s12886-026-04692-1","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,3]]},"assertion":[{"value":"15 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Formal ethics approval was not required under institutional policy. The participant provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the consent form is available for review by the journal\u2019s editorial office upon request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"112"}}